US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Militia Long/Short Equity ETF

38.88

+0.19150.49%

Volume:49.35K

Turnover:1.92M

Market Cap:354.60M

PE:- -

High:38.94

Open:38.78

Low:38.66

Close:38.69

52wk High:39.80

52wk Low:30.66

Shares:9.12M

Float Shares:9.12M

Volume Ratio:0.65

T/O Rate:0.54%

Dividend:- -

Dividend Rate:- -

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Cellectis Reports Full Year 2025 Financial Results and Provides a Business Update

NovaBridge Announces Productive FDA Type B Meeting on Potential Accelerated Approval Pathway for Givastomig in Gastric Cancer

CytomX’s Varsetatug Masetecan (EpCAM PROBODY® ADC) Continues to Demonstrate Positive Data Supporting Potential as a New Treatment Option in Late-Line Colorectal Cancer

SELLAS Life Sciences Announces Enrollment of First Patient in Newly Diagnosed First-Line AML Trial of SLS009

New Variable in Pan-KRAS Space: Valuation Gap Behind JAB-23E73's 38.5% ORR in Pancreatic Cancer

Press Release: Alpha Tau Announces Full Year 2025 Financial Results and Provides Corporate Update

Press Release: PMV Pharmaceuticals Reports Full Year 2025 Financial Results and Corporate Highlights

Press Release: BBOT Reports Fourth Quarter and Full Year 2025 Financial Results and Update on Corporate Progress

Press Release: Immatics Announces Full Year 2025 Financial Results and Business Update

InnoCare’s next-generation TRKi Zurletrectinib Receives Priority Review for the Treatment of Pediatric Patients with Solid Tumors in China

Press Release: ORYZON Reports Financial Results and Corporate Update for Quarter Ended December 31st, 2025

ALX Oncology Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Relay Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Outlines Anticipated 2026 Milestones

New England Journal of Medicine Publishes First-in-Human Rezatapopt Data Showing Selective Reactivation of Mutant p53 in Advanced Solid Tumors

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/stock/ORR/news?page=7"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"ORR","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ORR\",,,,,undefined,":{"symbol":"ORR","market":"US","secType":"STK","nameCN":"Militia Long/Short Equity ETF","latestPrice":38.8815,"timestamp":1787601600000,"preClose":38.69,"halted":0,"volume":49353,"delay":0,"changeRate":0.0049495993796848,"floatShares":9120000,"shares":9120000,"eps":0,"marketStatus":"Pre-Mkt","change":0.1915,"latestTime":"08-25 08:06:09 EDT","open":38.78,"high":38.935,"low":38.66,"amount":1915913.762742,"amplitude":0.007108,"askPrice":42.31,"askSize":100,"bidPrice":34.3,"bidSize":100,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1787664600000},"marketStatusCode":1,"adr":0,"exchange":"NASDAQ","adjPreClose":38.8815,"sharesOutstanding":12900000,"nav":38.62,"aum":352214400,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":38.85,"preClose":38.8815,"latestTime":"19:30 EDT","volume":11,"amount":427.8905,"timestamp":1787614207188,"change":-0.0315,"changeRate":-0.00081,"amplitude":0},"volumeRatio":0.6500590086906198,"impliedVol":0.1458,"impliedVolPercentile":0.538},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ORR\",,,,,undefined,":{"symbol":"ORR","floatShares":9120000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.6500590086906198,"shares":9120000,"dividePrice":0,"high":38.935,"amplitude":0.007108,"preClose":38.69,"low":38.66,"week52Low":30.655,"pbRate":"--","week52High":39.8,"institutionHeld":0,"latestPrice":38.8815,"eps":0,"divideRate":0,"volume":49353,"delay":0,"ttmEps":0,"open":38.78,"prevYearClose":34.16,"prevWeekClose":38.69,"prevMonthClose":38.79,"prevQuarterClose":36.32,"fiveDayClose":38.09,"twentyDayClose":37.26,"sixtyDayClose":36.22},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ORR\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ORR\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ORR\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ORR\",pageSize:20,pageCount:7,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2620779332","title":"Cellectis Reports Full Year 2025 Financial Results and Provides a Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2620779332","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620779332?lang=en_us&edition=fundamental","pubTime":"2026-03-20 07:21","pubTimestamp":1773962460,"startTime":"0","endTime":"0","summary":"Pivotal Phase 2 with lasme-cel in r/r B-ALL (BALLI-01 trial) ongoing Phase 1: 83% ORR at RP2D and 100% ORR in the target Phase 2 populationIn target Phase 2 population: 100% of patients became eligibl","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/19/3259513/0/en/Cellectis-Reports-Full-Year-2025-Financial-Results-and-Provides-a-Business-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CLLS","IE00B66KJ199.SGD","BK4139","IE00B7SZL793.SGD","LU0963586101.USD","BK4109","LU2463526074.USD","BK4097","ORR","BK4187","IE0031619046.USD","ASH","LU2065731478.USD","IE00B19Z4B17.USD","OS","CRS","BK4006"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619450780","title":"NovaBridge Announces Productive FDA Type B Meeting on Potential Accelerated Approval Pathway for Givastomig in Gastric Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2619450780","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619450780?lang=en_us&edition=fundamental","pubTime":"2026-03-16 19:00","pubTimestamp":1773658800,"startTime":"0","endTime":"0","summary":"FDA confirmed givastomig’s potential eligibility for an accelerated approval pathwayNovaBridge expects to initiate a registrational Phase 3 combination trial as early as Q4 2026, using objective respo","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/16/3256129/0/en/NovaBridge-Announces-Productive-FDA-Type-B-Meeting-on-Potential-Accelerated-Approval-Pathway-for-Givastomig-in-Gastric-Cancer.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LABU","BK4585","BK4588","ORR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619269450","title":"CytomX’s Varsetatug Masetecan (EpCAM PROBODY® ADC) Continues to Demonstrate Positive Data Supporting Potential as a New Treatment Option in Late-Line Colorectal Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2619269450","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619269450?lang=en_us&edition=fundamental","pubTime":"2026-03-16 19:00","pubTimestamp":1773658800,"startTime":"0","endTime":"0","summary":"- Confirmed response rates in expansion cohorts of32% at 10 mg/kg Q3W dose and 20% at 8.6 mg/kg Q3W - - Estimated progression free survival of 7.1 months at 10 mg/kg and 6.8 months at 8.6 mg/kg - - Gr","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/16/3256138/37704/en/CytomX-s-Varsetatug-Masetecan-EpCAM-PROBODY-ADC-Continues-to-Demonstrate-Positive-Data-Supporting-Potential-as-a-New-Treatment-Option-in-Late-Line-Colorectal-Cancer.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0456854461.SGD","LU0266512127.USD","BK4231","TRAE","ORR","BK4080","ADC","PFS","CRC","BK4213","BK4195","BK4211"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618412132","title":"SELLAS Life Sciences Announces Enrollment of First Patient in Newly Diagnosed First-Line AML Trial of SLS009","url":"https://stock-news.laohu8.com/highlight/detail?id=2618412132","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618412132?lang=en_us&edition=fundamental","pubTime":"2026-03-12 20:35","pubTimestamp":1773318900,"startTime":"0","endTime":"0","summary":"- Study to Enroll 80 Patients Unlikely to Benefit from Venetoclax/Azacitide (Aza/Ven) Therapy in the US and Europe -- SELLAS’ Predictive Biomarker and AI Assisted Precision Medicine Models to be Utili","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/12/3254670/0/en/SELLAS-Life-Sciences-Announces-Enrollment-of-First-Patient-in-Newly-Diagnosed-First-Line-AML-Trial-of-SLS009.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ORR","SLS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1170989075","title":"New Variable in Pan-KRAS Space: Valuation Gap Behind JAB-23E73's 38.5% ORR in Pancreatic Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=1170989075","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1170989075?lang=en_us&edition=fundamental","pubTime":"2026-03-11 09:27","pubTimestamp":1773192420,"startTime":"0","endTime":"0","summary":"Recent disclosures in the Pan-KRAS field have revealed a set of data worthy of close examination. JACOBIO-B (01167) announced Phase I study results for JAB-23E73 in pancreatic cancer patients. The...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","ORR","BK1161","01167"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618396674","title":"Press Release: Alpha Tau Announces Full Year 2025 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2618396674","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618396674?lang=en_us&edition=fundamental","pubTime":"2026-03-10 04:02","pubTimestamp":1773086520,"startTime":"0","endTime":"0","summary":"- Tremendous activity in recent months, including receipt of Japanese marketing approval, the fifth parallel U.S. trial approval, data from pancreatic cancer trials presented at ASCO GI Symposium, and the first brain cancer treatment -. \"The pace of progress at Alpha Tau today is unlike anything we've ever seen before,\" said Alpha Tau Chief Executive Officer Uzi Sofer. \"With a slew of meaningful announcements in the past few months, culminating most recently with our receipt of marketing approval in Japan, our first outside of Israel, and with multiple meaningful milestones targeted for the coming months, we remain laser focused on execution. Clinical trial progress remains our highest priority, with an astounding five clinical trials approved in parallel in the U.S. At the same time, we continue to build out our manufacturing capabilities in New Hampshire as well as our pre-commercial preparations, while entertaining multiple tracks of strategic dialogue with partners who show increas","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4022","ORR","BK4232","BK4082","IDE","DRTS","R"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617668076","title":"Press Release: PMV Pharmaceuticals Reports Full Year 2025 Financial Results and Corporate Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2617668076","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617668076?lang=en_us&edition=fundamental","pubTime":"2026-03-06 21:00","pubTimestamp":1772802000,"startTime":"0","endTime":"0","summary":"-- Enrollment remains on track in Phase 2 pivotal portion of PYNNACLE trial. ovarian cancer patients with a TP53 Y220C mutation. -- Rezatapopt granted Orphan Drug Designation by the U.S. Food and Drug. Administration for the treatment of TP53 Y220C positive ovarian cancer. -- New England Journal of Medicine published first-in-human rezatapopt data. showing selective reactivation of mutant p53 in advanced solid tumors. -- Cash, cash equivalents, and marketable securities of $112.9 million as of. December 31, 2025 providing expected cash runway to end of second quarter. PRINCETON, N.J., March 06, 2026  -- PMV Pharmaceuticals, Inc. , a precision oncology company pioneering the discovery and development of small molecule therapies targeting p53, today reported financial results for the full year ended December 31, 2025, and provided a corporate update.clinical trial. The multicenter, single-arm, registrational Phase 2 study. is assessing rezatapopt as monotherapy at a dose of 2000 mg once-","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4183","ALT","BK4139","BK4599","IE0009354923.USD","ORR","LU1878469433.USD","ODD","PMVP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617575291","title":"Press Release: BBOT Reports Fourth Quarter and Full Year 2025 Financial Results and Update on Corporate Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2617575291","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617575291?lang=en_us&edition=fundamental","pubTime":"2026-03-06 05:05","pubTimestamp":1772744700,"startTime":"0","endTime":"0","summary":"-- BBOT debuted as a publicly traded oncology company developing a. -- Announced encouraging preliminary safety and efficacy data across all. three programs: BBO-8520's differentiated efficacy and safety profile as. monotherapy and at active doses in combination with pembrolizumab with a. inhibitor, and BBO-10203 showing no hyperglycemia without HbA1c. \"2025 was a transformational year for BBOT as we debuted as a public company and advanced all three of our internally discovered RAS and PI3K<ALPHA> programs into clinical development,\" said Eli Wallace, PhD, Chief Executive Officer of BBOT. \"The preliminary safety and antitumor data across BBO-8520, BBO-11818, and BBO-10203 are consistent with a differentiated therapeutic index profile and reinforce the combination thesis underlying our portfolio. We believe we are uniquely positioned to pursue concurrent suppression of both the MAPK and PI3K<ALPHA> pathways -- a strategy made possible by our wholly owned, internally designed platform, ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PR","BK4139","BK4211","PRGS","BBOT","CRC","LU0266512127.USD","LU0456854461.SGD","BK4097","SOC","BK4195","ORR","PFS","BK4213","LU2065732104.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617604541","title":"Press Release: Immatics Announces Full Year 2025 Financial Results and Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2617604541","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617604541?lang=en_us&edition=fundamental","pubTime":"2026-03-05 20:00","pubTimestamp":1772712000,"startTime":"0","endTime":"0","summary":"randomized, controlled Phase 3 trial, SUPRAME, in previously treated. advanced melanoma ongoing; anzu-cel received Orphan Drug Designation from. the FDA for the treatment of both cutaneous and uveal melanoma. -- SUPRAME timelines remain unchanged; interim and final analyses remain. expected to be triggered in 2026, BLA submission in 1H 2027 and. -- IMA203CD8 PRAME Cell Therapy : Data update from ongoing Phase 1a. trial, with a focus on ovarian cancer at relevant doses, planned for. presentation at a major medical conference in 1H 2026. -- IMA402 PRAME Bispecific: RP2D determination and Phase 1 clinical data. update with focus on melanoma and gynecologic cancers treated with IMA402. monotherapy and combination with immune checkpoint inhibitor planned for. mRNA-4203 combination trial in 3Q 2025; TCER collaboration expanded. and milestone payment received in January 2026, with the first mRNA-based. TCER product candidate planned to advance into clinical development. -- Cash and cash equiv","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4211","BK4022","PFS","BK4232","BK4139","OS","R","ORR","BK4097","IMTX","BK4195"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616809485","title":"InnoCare’s next-generation TRKi Zurletrectinib Receives Priority Review for the Treatment of Pediatric Patients with Solid Tumors in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2616809485","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616809485?lang=en_us&edition=fundamental","pubTime":"2026-03-02 10:03","pubTimestamp":1772416980,"startTime":"0","endTime":"0","summary":"BEIJING, March  01, 2026  (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company for the treatment of cancer and autoimmune diseases, announced today that its next gene","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/02/3246995/0/en/InnoCare-s-next-generation-TRKi-Zurletrectinib-Receives-Priority-Review-for-the-Treatment-of-Pediatric-Patients-with-Solid-Tumors-in-China.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PFS","CDE","LU1223082196.USD","ORR","BK4097","LU1223082519.USD","BK4195","OS","LU1223083913.SGD","BK4211","BK4017"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614865082","title":"Press Release: ORYZON Reports Financial Results and Corporate Update for Quarter Ended December 31st, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2614865082","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614865082?lang=en_us&edition=fundamental","pubTime":"2026-02-28 01:29","pubTimestamp":1772213340,"startTime":"0","endTime":"0","summary":"-- Strong cash position at year-end 2025: $33.3 million . --    Appointed renowned Rolando Gutierrez-Esteinou, M.D.        --    Seven ongoing oncology trials, with six sponsored by. as new CMO for CNS                                      the NCI or top-tier U.S. institutions. --    Preparing protocol resubmission to incorporate FDA         --    Positive data in 1L AML unfit patients presented at. guidance on Phase III PORTICO-2 trial in aggression                       ASH with 100% ORR . in BPD                               --    Positive data in R/R FLT3+ AML presented at ASH; 67%. into additional EU countries                    --    Initiated enrollment in new Phase Ib trial in small. --    Finalizing preparations for new Phase II trial in                   cell lung cancer in combination with ICI and. aggression in autism spectrum disorder as a part of                                  radiotherapy. the IPCEI EU Grant in personalized medicine             --    Continued momentum ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4202","EMA","ET","LU2463526074.USD","BK4590","BK4588","BK4561","BK4081","BK4581","HSCT","SCD","ORR","CR","BK4144","NCI","OS","BK4097","ASH","BK4109","BK4161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614611859","title":"ALX Oncology Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2614611859","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614611859?lang=en_us&edition=fundamental","pubTime":"2026-02-27 21:00","pubTimestamp":1772197200,"startTime":"0","endTime":"0","summary":"- Clinical development for both the investigational CD47-inhibitor evorpacept and the novel EGFR-targeted antibody-drug conjugate ALX2004 remains on track following strong 2025 execution; company anti","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/27/3246481/0/en/ALX-Oncology-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results-and-Provides-Corporate-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4203","IE00BMG7P702.HKD","SITC","BK4161","OS","IE00BD4GTT62.SGD","IE00BMG7P587.USD","TRP","BK4231","BK4211","ALX","ASH","IE00BD4GTV84.USD","LU0456854461.SGD","HR","LU2463526074.USD","BK4566","CR","BK4225","LU0266512127.USD","IE00BMG7P819.SGD","ADC","BK4144","IE00BMG7P694.USD","BK4080","BK4097","IE00BD4GTW91.USD","BK4109","ORR","IE00BMG7P926.USD","CRC","BK4195","PFS","BK4213"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614071916","title":"Relay Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Outlines Anticipated 2026 Milestones","url":"https://stock-news.laohu8.com/highlight/detail?id=2614071916","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614071916?lang=en_us&edition=fundamental","pubTime":"2026-02-27 05:05","pubTimestamp":1772139900,"startTime":"0","endTime":"0","summary":"Initial Phase 1 data of zovegalisib in PIK3CA-driven vascular anomalies expected to be announced in first half of 2026 Breast cancer triplet data and frontline Phase 3 plans expected to be announced i","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/26/3246092/0/en/Relay-Therapeutics-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results-and-Outlines-Anticipated-2026-Milestones.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4135","BK4139","BK4195","WT","BK4563","BK4211","RLAY","ORR","PFS","IE00BHPRN162.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614044421","title":"New England Journal of Medicine Publishes First-in-Human Rezatapopt Data Showing Selective Reactivation of Mutant p53 in Advanced Solid Tumors","url":"https://stock-news.laohu8.com/highlight/detail?id=2614044421","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614044421?lang=en_us&edition=fundamental","pubTime":"2026-02-26 21:00","pubTimestamp":1772110800,"startTime":"0","endTime":"0","summary":"PRINCETON, N.J., Feb.  26, 2026  (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (“PMV Pharma” or the “Company”; Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of s","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/26/3245511/0/en/New-England-Journal-of-Medicine-Publishes-First-in-Human-Rezatapopt-Data-Showing-Selective-Reactivation-of-Mutant-p53-in-Advanced-Solid-Tumors.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AEIS","ORR","LU1815336091.USD","IE0031619046.USD","LU0757428866.USD","IE00B7SZL793.SGD","IE00B19Z4B17.USD","BK4157","IE00B66KJ199.SGD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":7,"pageCount":7,"totalSize":134,"code":"91000000","status":"200"}]}}